Pulmonary Hypertension & Lung Disease

Trial Objective

The purpose of this clinical trial is to determine the safety and effectiveness of an inhaled investigational medication, Treprostinil, in treating pulmonary hypertension related to Interstitial Lung Disease (ILD), including Combined Pulmonary Fibrosis and Emphysema (CPFE).

Pulmonary Hypertension & Lung Disease

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, call 303.270.2622 or complete the form below.

Who Can Participate

Individuals with pulmonary hypertension related to interstitial lung disease (ILD), including combined pulmonary fibrosis and emphysema (CPFE).


Estimated Time Commitment

7 visits over 20 weeks

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

United Therapeutics Corporation

Age

18+


Gender

Any Gender

Principal Investigators


Request More Information

*
*
*
*